{"id":280559,"date":"2016-10-05T11:00:00","date_gmt":"2016-10-05T11:00:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=d3a2f025ee5f64548fd7bf00ccbaba5a"},"modified":"2016-10-05T11:00:00","modified_gmt":"2016-10-05T11:00:00","slug":"ziopharm-to-present-at-the-jefferies-gene-editingtherapy-summit","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/ziopharm-to-present-at-the-jefferies-gene-editingtherapy-summit\/","title":{"rendered":"ZIOPHARM to Present at the Jefferies Gene Editing\/Therapy Summit"},"content":{"rendered":"<p align=\"justify\">BOSTON, Oct.  05, 2016  (GLOBE NEWSWIRE) &#8212; ZIOPHARM Oncology, Inc. (Nasdaq:<a href=\"http:\/\/globenewswire.com\/News\/Listing?symbol=ZIOP&#038;exchange=2\">ZIOP<\/a>) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies Gene Editing\/Therapy Summit on Tuesday, October 11, 2016 at 2:40 p.m. ET in New York City.<\/p>\n<p align=\"justify\"><strong>About ZIOPHARM Oncology, Inc.: <\/strong><\/p>\n<p align=\"justify\">ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company&#8217;s immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:<a href=\"http:\/\/globenewswire.com\/News\/Listing?symbol=XON&#038;exchange=4\">XON<\/a>) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation&#8217;s RheoSwitch Therapeutic System\u00ae technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company&#8217;s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.<\/p>\n<\/p>\n<pre>CONTACT: Contact:\nLori Ann Occhiogrosso\nZIOPHARM Oncology, Inc.\n617-259-1987\nlocchiogrosso@ziopharm.com\n\nDavid Pitts\nArgot Partners\n212-600-1902\ndavid@argotpartners.com<\/pre>\n","protected":false},"excerpt":{"rendered":"<p class=\"small\" align=\"justify\">BOSTON, Oct.  05, 2016  (GLOBE NEWSWIRE) &#8212; ZIOPHARM Oncology, Inc. (Nasdaq:<a href=\"http:\/\/globenewswire.com\/News\/Listing?symbol=ZIOP&amp;exchange=2\">ZIOP<\/a>) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies Gene Editing\/Therapy Summit on Tuesday, October 11, 2016 at 2:40 p.m. ET in New York City.<\/p>\n<p class=\"small\" align=\"justify\"><strong>About ZIOPHARM Oncology, Inc.: <\/strong><\/p>\n<p class=\"small\" align=\"justify\">ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company&#8217;s immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:<a href=\"http:\/\/globenewswire.com\/News\/Listing?symbol=XON&amp;exchange=4\">XON<\/a>) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation&#8217;s RheoSwitch Therapeutic System&reg; technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company&#8217;s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.<\/p>\n<\/p>\n<p class=\"small\"re>CONTACT: Contact:\nLori Ann Occhiogrosso\nZIOPHARM Oncology, Inc.\n617-259-1987\nlocchiogrosso@ziopharm.com\n\nDavid Pitts\nArgot Partners\n212-600-1902\ndavid@argotpartners.com<\/pre>\n","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71360],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/280559"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=280559"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/280559\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=280559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=280559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=280559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}